In The Know is an opportunity for existing and budding entrepreneurs, business founders, people running businesses, policymakers and the public at large who have an interest in learning from practitioners about the secrets of their success. At this session you will hear from Dr Chris Behrenbruch, Co-Founder and CEO of Telix Pharmaceuticals Limited (ASX:TLX).
The series is called In The Know since establishing any business venture requires its founders and leaders to be knowledgeable, informed, aware and up-to-date with a range of issues that come in to play in building a successful enterprise.
Thursday 25 October 2018
6:00 pm – 7:00 pm AEDT (light refreshments will be served at the conclusion of the talk)
Peter Doherty Institute for Infection and Immunity
792 Elizabeth Street
Melbourne, Victoria 3000
Guest speaker: Dr Chris Behrenbruch
Dr. Behrenbruch received a degree in electrical engineering and computer science from Monash University and received a D.Phil (Ph.D) in biomedical engineering from Oxford University in Sir Prof. Mike Brady’s “Medical Vision Laboratory” in the field of imaging and diagnosis of breast cancer. He also took additional graduate study in computational biology and genomics at Stanford University. He holds a Master of Business Administration (MBA) jointly awarded from New York University and the London School of Economics (TRIUM program) and has a strong background in corporate finance and negotiation. Dr Behrenbruch also holds a Juris Doctor (Law) from the University of Melbourne. Dr. Behrenbruch holds over 60 peer-reviewed publications and patents in the field of medical informatics, biotechnology and nanotechnology.
A serial entrepreneur, Dr. Behrenbruch started his career in the oil and gas industry and Siemens Telecommunications (Asia/Pacific). In the late 90’s, he was involved in starting several UK-based companies including Oxford Medical Image Analysis and Mirada Solutions.
From 2007–9, Dr. Behrenbruch was a Professor in the Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, at the University of California, Los Angeles (UCLA). His appointment at UCLA followed a successful track record in commercializing biotechnology, healthcare IT and medical devices. His laboratory focused on the technical and clinical challenges of introducing new device, instrumentation and nanotechnology solutions into the healthcare practice and he continues to teach in the area of life sciences commercialization and technology transfer. Dr. Behrenbruch was also a visiting academic and taught entrepreneurship classes at institutions in the United States, England, Germany, China and Australia.
Parallel to his prior academic role at UCLA, Dr. Behrenbruch was a Founder and Managing Partner of Momentum Biosciences LLC, a Los Angeles-based early stage venturing and business advisory group. Momentum Biosciences manages a fully staffed and equipped biotechnology incubator facility in Culver City (Los Angeles) in close proximity to UCLA.
In June 2009, Dr. Behrenbruch left his management role at Momentum to take the position of CEO at ImaginAb, Inc (until Feb, 2015). ImaginAb was the first Momentum portfolio company to “graduate” from its venture accelerator program and has raised a total of $50m in venture capital. He was also the non-executive Chairman of Cell Therapies Pty Ltd, a private-public partnership with the Peter MacCallum Cancer Center in Melbourne, Australia.
Dr Behrenbruch is currently co-founder and CEO of Telix Pharmaceuticals Limited (ASX:TLX) and a non-executive director of Factor Therapeutics (ASX:FTT) and Amplia Therapeutics (ASX:ATX).